Assessment of QTc prolongation following thioridazine withdrawal in a developmentally disabled population [2]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3, 2003, Pages 314-315

  Brahm, Nancy C ^a   Buswell, Arthur ^a   Christensen, Dix ^a   Brown, Robert D ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESORIDAZINE; THIORIDAZINE;

DEVELOPMENTAL DISORDER; DOSE RESPONSE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FOLLOW UP; HEART FUNCTION; HUMAN; LETTER; LONG QT SYNDROME; LONG TERM CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; WITHDRAWAL SYNDROME;

EID: 0038384117     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200306000-00014     Document Type: Letter

References (5)

1. Letter Dated July 1, 2000. East Hanover, NJ: Novartis Pharmaceuticals Corporation (59 Route 10, East Hanover, NJ 07936; 888-NOW-NOVARTIS or 888-669-6682); 2000.
2. Gutgesell H, Atkins D, Barst R, et al. AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry. 1999;38:1047-1050.
3. Carrillo J, Ramos S, Herraiz A, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19:494-499.
4. Hartigan-GO K, Bateman N, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60:543-553.
5. von Bahr C, Gunilla M, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991;49:234-240.